GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, has entered into a warrant inducement agreement with an existing institutional investor. The agreement facilitates the immediate exercise of existing warrants to purchase up to 5,697,628 shares of common stock at an exercise price of $0.64 per share, generating gross proceeds of approximately $3,646,482 before expenses. The company intends to use the net proceeds for working capital and general corporate purposes.
As an inducement for the immediate exercise, the investor will receive new unregistered warrants to purchase up to 11,395,256 shares of common stock. These new warrants carry the same exercise price of $0.64, become exercisable upon shareholder approval, and expire five years from that approval date. The transaction is expected to close on or about August 27, 2026, subject to customary conditions.
This strategic move provides GeoVax with essential capital to advance its pipeline, particularly its lead program GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. GEO-MVA is progressing under an expedited regulatory pathway, with plans for a pivotal Phase 3 clinical trial in the second half of 2026. The funding is critical for addressing global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness.
In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 trial in advanced head and neck cancer and is moving into combination strategies, including neoadjuvant and first-line settings.
The warrant inducement transaction underscores GeoVax's commitment to advancing its promising vaccine and cancer therapy candidates. By securing near-term funding, the company can continue its clinical development efforts and pursue strategic partnerships. For more information, visit GeoVax's website.
